Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | DRD1 | P21728 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30983972 | 0.86 | KDM4E (0.55) | KDM4EALDH1A1POLBDRD1PARP1 | |
| SCHEMBL8909081 | 0.81 | KDM4E (0.64) | KDM4EALDH1A1POLBHRH3SMN1; SMN2 | |
| SCHEMBL30983883 | 0.80 | KDM4E (0.65) | KDM4EALDH1A1POLBHRH3NPC1 | |
| SCHEMBL5755028 | 0.79 | KDM4E (0.71) | KDM4EALDH1A1THRBNPC1 | |
| SCHEMBL30984024 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1THRBPOLBHRH3 | |
| SCHEMBL30984092 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1THRBPOLBHRH3 | |
| SCHEMBL30984033 | 0.77 | KDM4E (0.55) | KDM4EALDH1A1POLBHRH3SMN1; SMN2 | |
| SCHEMBL29455752 | 0.76 | LTA4H (0.56) | KDM4EHRH3SMN1; SMN2 | |
| SCHEMBL1628165 | 0.74 | ALDH1A1 (0.57) | KDM4EALDH1A1HRH3NPC1SMN1; SMN2 | |
| SCHEMBL30983936 | 0.74 | MEN1 (0.50) | KDM4EALDH1A1POLBNPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| EP-4630410-A1 | POLQ INHIBITORS | Astrazeneca AB (SE) | 2025-10-15 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024121753-A1 | POLQ INHIBITORS | ASTRAZENECA AB (SE) | 2024-06-13 | — | — | WO | disclosed |